News
Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
16 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Reviva Pharmaceuticals Q4 EPS $(0.35) Misses $(0.32) Estimate
15 Apr 24
Earnings, News
Reviva to Present RECOVER Phase 3 Clinical Trial Data For Brilaroxazine In Schizophrenia At The ASCPT 2024 Annual Meeting
26 Mar 24
Biotech, News, General
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $20 Price Target
25 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Reviva to Host KOL Event To Discuss Topline Data From Phase 3 RECOVER Trial Of Brilaroxazine In Schizophrenia
6 Feb 24
Biotech, News, General
Press releases
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
25 Apr 24
Press Releases
REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm
25 Apr 24
News, Legal, Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
24 Apr 24
News, Legal, Press Releases
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
15 Apr 24
Health Care, Press Releases
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
15 Apr 24
Earnings, Press Releases
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
28 Mar 24
Health Care, Press Releases
Reviva to Present at the 36th Annual ROTH Conference
7 Mar 24
News, Press Releases